GlassScriptPhysician profile
Anna L Mapes
NPI 1053910703
$3,121.42
in general payments reported to CMS, 2019-2025
20 companies · $739 in 2025
The $739 reported for 2025 was more than what 80% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $75.41 · 2023: $808 · 2024: $1,499 · 2025: $739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,956 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,956.01 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $960.81 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $499.52 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $342.08 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Axsome Therapeutics, INC. | $231.18 | 2023-2025 | Auvelity |
| Astellas Pharma US INC | $212.04 | 2024-2025 | Veozah |
| Glaxosmithkline, LLC. | $177.82 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Bard Peripheral Vascular, INC. | $141.48 | 2023 | Venovo |
| Exact Sciences Corporation | $95.38 | 2023-2025 | Cologuard Collection Kit |
| Aimmune Therapeutics, INC. | $80.13 | 2025 | Zenpep |
| Verona Pharma, INC. | $62.72 | 2025 | Ohtuvayre |
| Hologic Sales and Service, LLC | $60.78 | 2024 | Thinprep 2000 Processor, Aptima |
| Indivior INC. | $46.55 | 2025 | Sublocade |
| Amgen INC. | $42.56 | 2022-2025 | Evenity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $42.53 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $39.18 | 2024-2025 | Rexulti |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $22.89 | 2024 | Spravato |
| Mylan Specialty L.P. | $19.53 | 2024 | Yupelri |
| Pfizer INC. | $16.83 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $13.79 | 2024 | Zoryve |
| Becton, Dickinson and Company | $13.62 | 2023 | Bd Affirm Vpiii Microbial Identification Test |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Mapes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.